Serina reports Q2 net loss of $8.9M, advances SER-252 trial ahead of schedule

Serina Therapeutics, Inc.

2026-Q2 EPS reported -$1.11

Net loss attributable to common shareholders was $8.9M, or $(0.55) per share, vs $6.6M loss ($(0.66)) in Q2 2025.
Operating expenses rose to $6.8M from $5.7M; R&D $3.8M, G&A $3.0M; cash $23.0M at June 30, 2026.
Completed enrollment/dosing of all 8 patients in Cohort 1 of SER-252 Phase 1b registrational study in July 2026, ahead of Q3 2026 guidance.
Top-line data from single-ascending-dose arm targeted for H1 2027; partnered with Gannet BioChem for process development and manufacturing.
Appointed Farrell Simon, Pharm.D., to Board of Directors and Audit/Compensation Committees in July 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.